Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Interchange of vaccine products, Neoplasm malignant
Clinical narrative: Cancer; Interchange of vaccine products; This spontaneous case was reported by a physician and describes the occurrence of NEOPLASM MALIGNANT (Cancer) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Previously administered products included for Product used for unknown indication: Pfizer COVID-19 vaccine (Dose 2) and Pfizer COVID-19 vaccine (Dose 1). Past adverse reactions to the above products included No adverse event with Pfizer COVID-19 vaccine and Pfizer COVID-19 vaccine.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NEOPLASM MALIGNANT (Cancer) (seriousness criterion medically significant) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). At the time of the report, NEOPLASM MALIGNANT (Cancer) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. The patient was just diagnosed with cancer before getting the second booster. No treatment information was provided.  Company comment: This spontaneous case concerns a 69-year-old male patient, with no reported medical history, who experienced the unexpected serious (medically significant) event of Neoplasm malignant that occurred on an unknown date after receiving the mRNA-1273 vaccine as 3rd dose. Onset latency cannot be assessed as the vaccination date and onset date of event were not provided. It was reported that patient was diagnosed with cancer before the second booster. Clinical course and treatment details were not reported. The outcome of event was unknown. On unknown dates, patient received 2 doses of Tozinameran vaccine as primary series prior to mRNA-1273 vaccine (Interchange of vaccine products noted). The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2022-636246 (Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 29-Aug-2022: Non significant follow-up contains reporter's  updated address.; Sender's Comments: This spontaneous case concerns a 69-year-old male patient, with no reported medical history, who experienced the unexpected serious (medically significant) event of Neoplasm malignant that occurred on an unknown date after receiving the mRNA-1273 vaccine as 3rd dose. Onset latency cannot be assessed as the vaccination date and onset date of event were not provided. It was reported that patient was diagnosed with cancer before the second booster. Clinical course and treatment details were not reported. The outcome of event was unknown. On unknown dates, patient received 2 doses of Tozinameran vaccine as primary series prior to mRNA-1273 vaccine (Interchange of vaccine products noted). The benefit-risk relationship of mRNA-1273 is not affected by this report. US-MODERNATX, INC.-MOD-2022-636246: